Cempra Company Profile (NASDAQ:CEMP)

About Cempra

Cempra logoCempra, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's lead product, solithromycin (CEM-101), is being developed in oral capsules, intravenous (IV), and suspension formulations, for the treatment of community-acquired bacterial pneumonia (CABP), as well as for the treatment of gonorrhea and other indications. Solithromycin has therapeutic potential and the spectrum of activity to target pathogenic bacteria. The Company also focuses on developing Taksta, which is an antibiotic known as fusidic acid, and is indicated as an oral treatment of acute bacterial skin and skin structure infections (ABSSSI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: CEMP
  • CUSIP: 15130J10
Key Metrics:
  • Previous Close: $25.21
  • 50 Day Moving Average: $23.15
  • 200 Day Moving Average: $18.96
  • 52-Week Range: $51,991,000.00 - $14.03
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.12
  • P/E Growth: 0.00
  • Market Cap: $1.31B
  • Outstanding Shares: 51,991,000
  • Beta: 1.29
Profitability:
  • Net Margins: -715.34%
  • Return on Equity: -63.54%
  • Return on Assets: -49.37%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 10.39%
  • Quick Ratio: 10.39%
Additional Links:
Companies Related to Cempra:

Analyst Ratings

Consensus Ratings for Cempra (NASDAQ:CEMP) (?)
Ratings Breakdown: 2 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $35.75 (41.81% upside)

Analysts' Ratings History for Cempra (NASDAQ:CEMP)
Show:
DateFirmActionRatingPrice TargetDetails
9/13/2016Raymond James Financial Inc.Initiated CoverageOutperform$32.00View Rating Details
8/3/2016Needham & Company LLCReiterated RatingBuy$48.00View Rating Details
8/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details
8/2/2016Robert W. BairdReiterated RatingOutperform$33.00View Rating Details
8/2/2016Jefferies GroupLower Price TargetBuy$42.00 -> $40.00View Rating Details
7/12/2016JPMorgan Chase & Co.Initiated CoverageOverweight$31.00View Rating Details
7/5/2016WBB SecuritiesReiterated RatingBuy$40.00View Rating Details
6/24/2016Stifel NicolausLower Price TargetBuy$51.00 -> $47.00View Rating Details
6/7/2016Roth CapitalInitiated CoverageBuy$37.00View Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldView Rating Details
11/16/2015Morgan StanleyUpgradeEqual Weight -> Overweight$25.00 -> $38.00View Rating Details
6/18/2015SunTrust Banks Inc.Reiterated RatingBuy$50.00View Rating Details
1/5/2015Ladenburg ThalmannReiterated RatingBuy$17.00 -> $34.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Cempra (NASDAQ:CEMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/20/2016        
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/2/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.42)($0.57)$4.21 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.49)($0.46)$3.19 millionViewListenView Earnings Details
10/29/2014Q314($0.56)($0.34)$7.80 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cempra (NASDAQ:CEMP)
Current Year EPS Consensus Estimate: $-2.63 EPS
Next Year EPS Consensus Estimate: $-2.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.61)($0.48)($0.56)
Q2 20166($0.68)($0.44)($0.58)
Q3 20165($0.78)($0.46)($0.62)
Q4 20165($0.94)($0.63)($0.78)
Q1 20171($1.01)($1.01)($1.01)
Q2 20171($0.94)($0.94)($0.94)
Q3 20171($0.77)($0.77)($0.77)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cempra (NASDAQ:CEMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cempra (NASDAQ:CEMP)
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 78.31%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cempra (NASDAQ:CEMP)
DateHeadline
News IconHot Biotech Stocks Recap: Fate Therapeutics, Inc. (NASDAQ:FATE), Cempra, Inc. (NASDAQ:CEMP) - The Voice Registrar (NASDAQ:CEMP)
voiceregistrar.com - September 23 at 3:34 PM
News IconCempra Inc (CEMP) to Post Q2 2016 Earnings of ($0.54) Per Share, Roth Capital Forecasts - DailyQuint (NASDAQ:CEMP)
dailyquint.com - September 22 at 4:18 PM
News Icon2 Biotech Stocks News And Price Trends: Cempra, Inc. (NASDAQ:CEMP), Sage Therapeutics, Inc. (NASDAQ:SAGE) - The Voice Registrar (NASDAQ:CEMP)
voiceregistrar.com - September 22 at 4:18 PM
News IconThe Key Numbers To Watch From Cempra, Inc. (NASDAQ:CEMP)'s ... - The Voice Registrar (NASDAQ:CEMP)
voiceregistrar.com - September 22 at 4:18 PM
nasdaq.com logoCommit To Buy Cempra At $15, Earn 19.3% Using Options (NASDAQ:CEMP)
www.nasdaq.com - September 21 at 4:48 PM
News IconCempra Inc (CEMP) Coverage Initiated by Analysts at Roth Capital - DailyQuint (NASDAQ:CEMP)
dailyquint.com - September 21 at 8:10 AM
nasdaq.com logoCommit To Buy Cempra At $15, Earn 19.3% Using Options - Nasdaq (NASDAQ:CEMP)
www.nasdaq.com - September 21 at 8:10 AM
News IconNotable Monday Option Activity: CEMP, STZ, X (NASDAQ:CEMP)
www.stockoptionschannel.com - September 19 at 4:59 PM
News IconStock Perspective: Cempra, Inc. (NASDAQ:CEMP) Company Earnings Watch - Frisco Fastball (NASDAQ:CEMP)
friscofastball.com - September 19 at 8:54 AM
News IconQuarterly EPS analysis of Cempra, Inc. (NASDAQ:CEMP) - Newburgh Press (NASDAQ:CEMP)
newburghpress.com - September 18 at 8:52 AM
News IconKilduff header gives Dundalk a Europa League point against AZ Alkmaar (NASDAQ:CEMP)
avauncer.com - September 17 at 8:56 AM
directorstalkinterviews.com logoCempra Inc 39% Potential Upside Now Implied by Raymond James - DirectorsTalk Interviews (NASDAQ:CEMP)
www.directorstalkinterviews.com - September 14 at 8:23 AM
finance.yahoo.com logoCoverage initiated on Cempra by Raymond James (NASDAQ:CEMP)
finance.yahoo.com - September 14 at 8:23 AM
News IconCempra expects FDA OK for Solithromycin by end of year (NASDAQ:CEMP)
www.heraldsun.com - September 11 at 3:56 PM
News IconCempra expects FDA OK for Solithromycin by end of year - Durham Herald Sun (NASDAQ:CEMP)
www.heraldsun.com - September 10 at 8:50 AM
News IconCempra expects FDA approval for pneumonia drug by end of the year - WRAL Tech Wire (NASDAQ:CEMP)
wraltechwire.com - September 9 at 4:02 PM
benzinga.com logoWatch These 5 Huge Put Purchases In Friday Trade - Benzinga (NASDAQ:CEMP)
www.benzinga.com - September 9 at 4:02 PM
capitalcube.com logoETF’s with exposure to Cempra, Inc. : September 9, 2016 (NASDAQ:CEMP)
www.capitalcube.com - September 9 at 4:02 PM
News IconCempra expects FDA approval for pneumonia drug by end of the year (NASDAQ:CEMP)
wraltechwire.com - September 9 at 8:59 AM
News IconThe Key Numbers To Watch From Cempra, Inc. (NASDAQ:CEMP)'s Earnings - The Voice Registrar (NASDAQ:CEMP)
voiceregistrar.com - September 7 at 4:11 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Biogen, ImmunoGen, Jazz Pharma, and Cempra (NASDAQ:CEMP)
www.prnewswire.com - September 7 at 9:19 AM
finance.yahoo.com logoCempra to Present at Three Upcoming Investor Conferences (NASDAQ:CEMP)
finance.yahoo.com - September 1 at 12:33 PM
News IconShares Gapping Higher Pre-Bell: Cempra, Inc. (NASDAQ:CEMP) - Post News (NASDAQ:CEMP)
www.kentuckypostnews.com - August 31 at 4:07 PM
News IconNotable Stocks in the Spotlight: Cavium Inc (NASDAQ:CAVM), Cempra Inc (NASDAQ:CEMP), Emerson Electric Co ... - NYSE Journal (press release) (NASDAQ:CEMP)
stockznews.com - August 31 at 4:06 PM
rttnews.com logoCEMP To Face FDA Panel, RIGL On A High, FDA Nod For Erelzi, KPTI Awaits STORM (NASDAQ:CEMP)
www.rttnews.com - August 31 at 8:57 AM
reuters.com logoBRIEF-Cempra says FDA scheduled meeting to discuss safety, efficacy of solithromycin (NASDAQ:CEMP)
www.reuters.com - August 30 at 4:10 PM
streetinsider.com logoCempra (CEMP) Announces Date for FDA Meeting on Solithromycin as CABP Treatment (NASDAQ:CEMP)
www.streetinsider.com - August 30 at 12:03 PM
investornewswire.com logoCan Shares Of Cempra, Inc. (NASDAQ:CEMP) Get To $51? - Investor Newswire (NASDAQ:CEMP)
www.investornewswire.com - August 29 at 8:39 PM
News IconNews Recap: Cempra Inc (NASDAQ:CEMP), Biogen Inc (NASDAQ:BIIB), Kimberly Clark Corp(NYSE:KMB) - NYSE Journal (press release) (NASDAQ:CEMP)
stockznews.com - August 29 at 3:32 PM
smarteranalyst.com logoCompany Update (NASDAQ:CEMP): Cempra Inc's Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin ... - Smarter Analyst (NASDAQ:CEMP)
www.smarteranalyst.com - August 26 at 11:58 AM
News IconStocks to Track: Cempra Inc (NASDAQ:CEMP), Yirendai Ltd - ADR(NYSE:YRD) - NYSE Journal (press release) (NASDAQ:CEMP)
stockznews.com - August 25 at 4:11 PM
capitalcube.com logoETF’s with exposure to Cempra, Inc. : August 25, 2016 (NASDAQ:CEMP)
www.capitalcube.com - August 25 at 4:11 PM
finance.yahoo.com logoCempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases (NASDAQ:CEMP)
finance.yahoo.com - August 25 at 4:11 PM
News IconCempra’s Application for Pneumonia Drug Validated in EU (NASDAQ:CEMP)
mrtopstep.com - August 25 at 9:01 AM
News IconEuropean regulators validate Cempra pneumonia treatment (NASDAQ:CEMP)
wraltechwire.com - August 24 at 11:37 AM
News IconWorth Watching Stocks News Buzz: Nike Inc (NYSE:NKE), Cempra Inc (NASDAQ:CEMP) - NYSE Journal (press release) (NASDAQ:CEMP)
stockznews.com - August 23 at 9:21 PM
smarteranalyst.com logoCompany Update (NASDAQ:CEMP): Cempra Inc Announces European Medicines Agency Validates MAA for ... - Smarter Analyst (NASDAQ:CEMP)
www.smarteranalyst.com - August 23 at 9:21 PM
4-traders.com logoCEMPRA, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:CEMP)
www.4-traders.com - August 23 at 4:16 PM
smarteranalyst.com logoCompany Update (NASDAQ:CEMP): Cempra Inc Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP (NASDAQ:CEMP)
www.smarteranalyst.com - August 23 at 4:16 PM
bizjournals.com logoEuropean regulators validate Cempra's drug application (NASDAQ:CEMP)
www.bizjournals.com - August 23 at 4:16 PM
biz.yahoo.com logoCEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CEMP)
biz.yahoo.com - August 23 at 4:16 PM
News IconSell-side & Crowd View on Cempra, Inc. (NASDAQ:CEMP) - Post News (NASDAQ:CEMP)
www.kentuckypostnews.com - August 23 at 8:18 AM
finance.yahoo.com logo7:30 am Cempra announces that the EMA has validated its MAA seeking approval of oral capsule and IV formulations of solithromycin for the treatment of community-acquired bacterial pneumonia (NASDAQ:CEMP)
finance.yahoo.com - August 23 at 8:18 AM
finance.yahoo.com logoCempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP (NASDAQ:CEMP)
finance.yahoo.com - August 23 at 8:18 AM
News IconNews Review: Crown Crafts, Inc. (NASDAQ:CRWS), Cempra Inc ... - NYSE Journal (press release) (NASDAQ:CEMP)
stockznews.com - August 15 at 9:46 PM
investornewswire.com logoWill Cempra, Inc. (NASDAQ:CEMP) Hit $51 Price Target? - Investor Newswire (NASDAQ:CEMP)
www.investornewswire.com - August 15 at 9:46 PM
biz.yahoo.com logoCEMPRA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:CEMP)
biz.yahoo.com - August 11 at 9:59 PM
finance.yahoo.com logoCempra Appoints Dr. David Zaccardelli to Board of Directors (NASDAQ:CEMP)
finance.yahoo.com - August 11 at 4:14 PM
seekingalpha.com logoLong Cempra: Multiple Catalysts For An Easy 60% Upside - Seeking Alpha (NASDAQ:CEMP)
seekingalpha.com - August 11 at 12:19 PM
equities.com logoCempra Inc. (CEMP) is Trading Lower on Unusual Volume for August 08 (NASDAQ:CEMP)
www.equities.com - August 10 at 11:35 AM

Social

Cempra (NASDAQ:CEMP) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff